Search Result

Results for "

AML，MOLM-13

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (23) Autophagy (1) Bacterial (1) Bcl-2 Family (3) Caspase (1) CDK (4) Dihydroorotate Dehydrogenase (1) DNA Methyltransferase (1) DNA/RNA Synthesis (2) E3 Ligase Ligand-Linker Conjugates (4) Epigenetic Reader Domain (6) ERK (1) Eukaryotic Initiation Factor (eIF) (1) Fat Mass and Obesity-associated Protein (FTO) (3) FLT3 (14) HDAC (1) Histone Demethylase (1) IKZF Family (1) JAK (1) Ligands for Target Protein for PROTAC (2) MDM-2/p53 (1) METTL3 (4) Mitochondrial Metabolism (1) MNK (1) Molecular Glues (1) mTOR (1) p38 MAPK (1) p97 (1) PARP (2) Phosphatase (1) PI3K (1) PROTAC Linkers (2) PROTACs (10) Ras (1) Reactive Oxygen Species (ROS) (1) SHP2 (1) STAT (3) YTHDF (1)
By Research Areas:	Cancer (54) Infection (1)

By Targets:

Akt (2)

Apoptosis (23)

Autophagy (1)

Bacterial (1)

Bcl-2 Family (3)

Caspase (1)

CDK (4)

Dihydroorotate Dehydrogenase (1)

DNA Methyltransferase (1)

DNA/RNA Synthesis (2)

E3 Ligase Ligand-Linker Conjugates (4)

Epigenetic Reader Domain (6)

ERK (1)

Eukaryotic Initiation Factor (eIF) (1)

Fat Mass and Obesity-associated Protein (FTO) (3)

FLT3 (14)

HDAC (1)

Histone Demethylase (1)

IKZF Family (1)

JAK (1)

Ligands for Target Protein for PROTAC (2)

MDM-2/p53 (1)

METTL3 (4)

Mitochondrial Metabolism (1)

MNK (1)

Molecular Glues (1)

mTOR (1)

p38 MAPK (1)

p97 (1)

PARP (2)

Phosphatase (1)

PI3K (1)

PROTAC Linkers (2)

PROTACs (10)

Ras (1)

Reactive Oxygen Species (ROS) (1)

SHP2 (1)

STAT (3)

YTHDF (1)

By Research Areas:

Cancer (54)

Infection (1)

Targets Recommended: CX3CR1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-161615

PROTAC ATR degrader-2	Apoptosis PROTACs	Cancer
PROTAC ATR degrader-2 (Compound 8i) is a PROTAC degrader for ATR, through of . PROTAC ATR degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC₅₀ of 22.9 and 34.5 nM. APROTAC ATR degrader-2 induces apoptosis, inhibits proliferations of AML cells. PROTAC ATR degrader-2 exhibits good pharmacokinetics charachers and antitumor efficacy against AML in mouse model. (Pink: ATR ligand (HY-161616); Blue:E3 ligase ligand Lenalidomide (HY-A0003); Black: linker)

HY-168741

FLT3-ITD-IN-2	FLT3	Cancer
FLT3-ITD-IN-2 (Compound A1) is an inhibitor for FLT3-ITD kinase with an IC₅₀ of 2.12 nM. FLT3-ITD-IN-2 inhibits the proliferation of FLT3-dependent human AML cell line MOLM-13 with an IC₅₀ of 25.65 nM. FLT3-ITD-IN-2 exhibits antitumor efficacy against acute myeloid leukemia .

HY-170558

FW-1	FLT3 Apoptosis	Cancer
FW-1 is a type I inhibitor for FLT3 with IC₅₀ of ca. 1 μM. FW-1 exhibits cytotoxicity in FLT3 mutated AML cell. FW-1 arrests the cell cycle at G0/G1 phase, and induces apoptosis in cell MV4-11 and MOLM-13 .

HY-175473

HI042	FLT3 Apoptosis	Cancer
HI042 is a FMS-like Tyrosine Kinase 3 (FLT3) inhibitor. HI042 shows IC₅₀ values of 0.62 μM for MOLM-13, 0.33 μM for MV4-11, and 0.89 μM for OCI-AML3 cells. HI042 selectively reduces the viability of FLT3-internal tandem duplication (FLT3-\|TD) mutations-positive cell lines, induces apoptosis, disrupts cell cycle progression, and diminishes the clonogenic potential. HI042 can be used for the research of acute myeloid leukemia (AML) .

HY-174911

FLT3-IN-33	FLT3 Apoptosis	Cancer
FLT3-IN-33 (Compound 7r) is a FLT3 inhibitor with an IC₅₀ of 7.82  nM. FLT3-IN-33 has superior anticancer activities against acute myeloid leukemia (AML) cells, such as MV4-11 and MOLM-13 cells. FLT3-IN-33 significantly induces cell apoptosis and inhibits phosphorylation of FLT3 pathways. FLT3-IN-33 can be used for AML and other cancers research .

HY-174847

VCP/p97 IN-2	p97	Cancer
VCP/p97 IN-2 (Compound V13) is a VCP/p97 inhibitor with IC₅₀ of 32 nM for p97. VCP/p97 IN-2 has excellent antitumor activities and significantly inhibits tumor growth in Molm-13 xenograft mice model. VCP/p97 IN-2 can be used for acute myeloid leukemia (AML) research .

HY-174827

POLRMT-IN-2	Mitochondrial Metabolism Reactive Oxygen Species (ROS) Apoptosis	Cancer
POLRMT-IN-2 is a potent POLRMT inhibitor. POLRMT-IN-2 exhibits strong antiproliferative activity in MOLM-13 cells, with an IC₅₀ of 1.01 μM. POLRMT-IN-2 disrupts mitochondrial function and induces apoptosis in MOLM-13cells. POLRMT-IN-2 can be used for the study of acute myeloid leukemia(AML) .

HY-143238

FY-56	Histone Demethylase	Cancer
FY-56 is a highly potent and selective LSD1/KDM1A inhibitor (IC₅₀=42 nM) and exhibits high selectivity over MAO-A/B. FY-56 induces differentiation of MOLM-13 and MV4-11 cell and has the potential for AML research .

HY-173141

mTOR inhibitor-26	mTOR	Cancer
mTOR inhibitor-26 (Compound HPT-11) is an inhibitor of mTOR with an IC₅₀ of 0.7 nM. It effectively inhibits the proliferation of AML cell lines Molm-13 and MV-4-11. mTOR inhibitor-26 exhibits antitumor activity and favorable metabolic stability, making it a promising candidate for cancer research .

HY-162293

CDK8-IN-14	CDK	Cancer
CDK8-IN-14 (compound 12) inhibits CDK8 with an IC₅₀ value of 39.2 nM and has anti-AML cell proliferation activity (molm-13 GC50 = 0.02±0.01μM, MV4-11 GC50 = 0.03±0.01μM) .

HY-155770

FLT3-IN-20	FLT3	Cancer
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor with IC₅₀ values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. FLT3-IN-20 has anti-proliferation efficacy in FLT3-ITD-positive AML cell lines MV4-11 and MOLM-13 (7 and 9 nM, respectively) and the MOLM-13 variant (4 nM) with the FLT3-ITD-D835Y mutation. FLT3-IN-20 can be used in research of cancer .

HY-156759

METTL3-IN-5	METTL3	Cancer
METTL3-IN-5 (Compound 13) is a METTL3 inhibitor. METTL3-IN-5 inhibits MOLM-13 growth with an IC₅₀ less than 2 μM. METTL3-IN-5 has weak hERG inhibitory activity (IC₅₀ >30 μM). METTL3-IN-5 can be used for AML research .

HY-168936

DP-15	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
DP-15 is the degrader for GSPT1 and BRD4 with DC₅₀s of 5.25 nM and 0.48 nM. DP-15 exhibits anti-proliferative activity of AML cells and NHL cells with an IC₅₀ of nanomolar levels, arrests the cell cycle at G1 phase, and induces apoptosis in MOLM13. DP-15 exhibits anti-leukemia activity in MOLM-13 xenograft mouse models . (Pink: ligand for target protein JQ-1 carboxylic acid (HY-78695); Black: linker (HY-W262798); Blue: ligand for E3 ligase Cereblon Thalidomide-5-OH (HY-23095))

HY-147716

CDK8-IN-6	CDK	Cancer
CDK8-IN-6 (compound 9) is a potent cyclin-dependent kinase 8 (CDK8) inhibitor with an K_d of 13 nM. CDK8-IN-6 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC₅₀s of 11.2, 7.5, 8.6, 20.5, 12.5-25 µM, respectively. CDK8-IN-6 has the potential for the research of AML-cancer .

HY-175783

MM927	Apoptosis	Cancer
MM927 is a potent NVL inhibitor, with an IC₅₀ of 0.053 μM. MM927 blocks 60S ribosomal subunit biogenesis in the nucleolus. MM927 induces half-mer polysomes, cell cycle arrest at G1/S and G2/M and apoptosis in cells. MM927 demonstrates antitumor efficacy in MOLM-13 AML and HCT116 CRC xenograft models. MM927 can be used for the study of cancers such as acute myeloid leukemia (AML) and colorectal cancer (CRC) .

HY-170576

FLT3-IN-28	FLT3 STAT Apoptosis	Cancer
FLT3-IN-28 (Compound 12y) is an orally active FLT3 inhibitor with antitumor activity. FLT3-IN-28 selectively inhibits cancer cells harboring the FLT3 internal tandem duplication (ITD) mutation, with IC₅₀ values of 85, 290, 130, 65, and 220 nM for BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines respectively (MV4-11 and MOLM-13/14 are acute myeloid leukemia (AML) cell lines carrying the FLT3-ITD mutation). Additionally, FLT3-IN-28 can downregulate the phosphorylation levels of FLT3 and STAT5 in MOLM-13 cells and induce cell cycle arrest and Apoptosis. FLT3-IN-28 has an oral bioavailability of 19.2% in SD rats and can prolong survival in a dose-dependent manner in NSG mice xenografted with MOLM-13 cells. FLT3-IN-28 holds promise for research in cancer fields related to FLT3-ITD .

HY-172581

Clifutinib	FLT3 Apoptosis Ras p38 MAPK PI3K Akt JAK STAT	Cancer
Clifutinib is an orally active and selective internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) inhibitor with an IC₅₀ value of 15.1 nM. Clifutinib exerts strong antiproliferative effects on FLT3-ITD acute myeloid leukemia (AML) cell lines (MV-4-11: IC₅₀ = 1.5 nM; MOLM-13: IC₅₀ = 1.4 nM). Clifutinib inhibits the activity of FLT3-ITD kinase and blocks the downstream RAS/MAPK, PI3K/AKT, and JAK/STAT5 signaling pathways of FLT3. Clifutinib induces apoptosis of acute myeloid leukemia (AML) cells with FLT3-ITD mutations. Clifutinib demonstrates significant antitumor efficacy in mice bearing MV-4-11 or MOLM-13 xenografts. Clifutinib is promising for research of relapsed/refractory FLT3-ITD-positive acute myeloid leukemia .

HY-147717

CDK8-IN-7	CDK	Cancer
CDK8-IN-7 (compound 12) is a potent and selective cyclin-dependent kinase 8 (CDK8) inhibitor with an K_d of 3.5 nM. CDK8-IN-7 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC₅₀s of 5.9, 4.8, 5.4, 16.2, 12.5-25 µM, respectively. CDK8-IN-7 has the potential for the research of AML-cancer .

HY-115906

K783-0308	FLT3 MNK Apoptosis	Cancer
K783-0308 is a potent and selective dual inhibitor of FLT3 and MNK2 with IC₅₀ values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC₅₀=10.5 µM) and MV-4-11 (IC₅₀=10.4 µM) cells. K783-0308 promotes acute myeloid leukemia (AML) cell apoptosis and cell cycle arrests in the G0/G1 phase .

HY-162930

PROTAC METTL3 degrader 1	PROTACs METTL3	Cancer
PROTAC METTL3 degrader 1 (Compound KH12) is a VHL-based PROTAC METTL3 degrader (DC₅₀: 220 nM in MOLM-13 cells). PROTAC METTL3 degrader 1 inhibits METTL3/14 complex with an IC₅₀ value of 341 nM. PROTAC METTL3 degrader 1 has anti-proliferative activities against AML cells. Black: Linker (HY-ER002); Red: METTL3 ligand (HY-115717); Blue: VHL ligand (HY-120217) .

HY-174873

AF151	PROTACs METTL3 Apoptosis Bcl-2 Family	Cancer
AF151 is a METTL3 PROTAC degrader with the DC₅₀ of 0.43 μM in MOLM-13 cells. AF151 inhibits cell growth by significantly degrading METTL3 protein and reducing m6A levels. AF151 can induce cell apoptosis and reduce the level of Bcl-2 protein. AF151 can be used for research on cancer such as acute myeloid leukemia (AML). (Pink: METTL3 Ligand (HY-174874); Blue: VHL Ligand (HY-125845); Black: Linker; VHL Ligand+Linker (HY-174875)) .

HY-173481

CDK9-IN-37	CDK	Cancer
CDK9-IN-37 (Compound 24) is a CDK9 inhibitor (EC₅₀: 5.5 nM) with weak inhibition on other CDK isoforms, showing high selectivity. CDK9-IN-37 has significant antiproliferative activity against acute myeloid leukemia MOLM-13 cells (IC₅₀: 0.034 μM). CDK9-IN-37 inhibits the CDK9 signaling pathway, reduces the phosphorylation level of RNAP II CTD (Ser2), downregulates the anti-apoptotic protein McI-1, induces cell apoptosis, and arrests the cell cycle at the G2/M phase. CDK9-IN-37 can be used in the study of acute myeloid leukemia (AML) .

HY-172399

FTO-IN-14	Fat Mass and Obesity-associated Protein (FTO) Apoptosis	Cancer
FTO-IN-14 (Compound F97) is the inhibitor for the RNA demethylase Fat mass and obesity-associated protein FTO with IC₅₀ of 0.45 μM. FTO-IN-14 regulates the protein expression of ASB2, RARA and MYC. FTO-IN-14 exhibits antiproliferative activity in AML cancer cells (IC₅₀ for MOLM13, NB4, HEL, OCI-AML3, MV4-11 and MONOMAC6 is 0.7-5.5 μM), induces apoptosis in NB4 cell. FTO-IN-14 exhibits antitumor activity in mouse NB4 xenograft models .

HY-149522

WK499	Bcl-2 Family Apoptosis	Cancer
BCL6-IN-10 (Compound WK499) is a BCL6 inhibitor. BCL6-IN-10 interrupts the binding of BCL6 to SMRT protein. BCL6-IN-10 induces cell apoptosis, cell cycle arrest and DNA damage. BCL6-IN-10 inhibits AML cell proliferation (IC₅₀s: 0.91, 1.63, 1.026, 7.42, 0.87, 0.85μM for OCl-AML3, THP1, MOLM13, HL60, KG1, NB4 cell respectively) .

HY-178020

FLT3-IN-34	FLT3 ERK Akt Apoptosis	Cancer
FLT3-IN-34 is a FLT3 inhibitor, with an IC₅₀ value of 1.4 nM. FLT3-IN-34 blocks the phosphorylation of FLT3 and its downstream signaling molecules AKT and ERK1/2. FLT3-IN-34 induces concentration-dependent G0/G1 phase arrest and mild apoptosis in FLT3-ITD-positive MV4-11 cells. FLT3-IN-34 shows potent anti-proliferative activity against FLT3-ITD-positive MV4-11 cells (IC₅₀ = 14.95 nM) and MOLM-13 (IC₅₀ = 18.5 nM). FLT3-IN-34 can be used for the study of FLT3-positive acute myeloid leukemia (AML) .

HY-162642

Bfl-1-IN-3	Bcl-2 Family	Cancer
Bfl-1-IN-3 (Compound 56) is a selective, competitive inhibitor for Bfl-1 on BID binding site with K_i of 105 nM. Bfl-1-IN-3 inhibits the proliferation of cell pfeiffer and MV4-11, with IC₅₀ of 6.92 μM and 12.6 μM. Bfl-1-IN-3 induces apoptosis in pfeiffer cells. Bfl-1-IN-3 overcomes Venetoclax (HY-15531) resistance at the cellular level, and shows synergistically enhanced anti-tumor activity with Venetoclax .

HY-154997

7OQL	METTL3	Cancer
7OQL (compound 54) is a selective METTL3 inhibitor (IC₅₀=0.054 µM). 7OQL has the potential to be used in the study of cancer .

HY-148422

Rohinitib 1 Publications Verification	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML .

HY-175520

SHP2-IN-42	SHP2 Phosphatase Apoptosis	Cancer
SHP2-IN-42 is a src homology 2 domain-containing phosphatase 2 (SHP2) inhibitor with an IC₅₀ of 15 nM. SHP2-IN-42 inhibits cell proliferation and induces apoptosis and G1 phase cell cycle arrest. SHP2-IN-42 can be used for the research of cancer, such as acute myeloid leukemia (AML) .

HY-170452

MDM2 ligand 4	MDM-2/p53 Ligands for Target Protein for PROTAC	Cancer
MDM2 ligand 4 is the ligand for MDM2 that can be used for synthesis of PROTAC degrader KT-253 (HY-170451) .

HY-161495

CBP/p300 ligand 4	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC₅₀ of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300 .

HY-144711

FLT3/ITD-IN-3	FLT3	Cancer
FLT3/ITD-IN-3 (Compound 19) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 0.9 nM against FLT3 ^D835Y, FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-3 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-144709

FLT3/ITD-IN-1	FLT3	Cancer
FLT3/ITD-IN-1 (Compound 1) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 38.2 nM and 144.1 nM against FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-1 displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-173333

PROTAC SMARCA2/4 degrader-38	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
PROTAC SMARCA2/4 degrader-38 is a degrader SMARCA2/4 PROTAC (DC₅₀: 3.0 nM and 4.0 nM respectively). PROTAC SMARCA2/4 degrader-38 promotes the ubiquitination and degradation of SMARCA2/4. PROTAC SMARCA2/4 degrader-38 blocks the G0/G1 cell cycle and induces apoptosis. PROTAC SMARCA2/4 degrader-38 can be used in acute myeloid leukemia (AML) research. (Pink: SMARCA2/4 ligand; Blue: VHL ligand (HY-112078); Black: linker; Target Protein Ligand-Linker Conjugates (HY-173343)) .

HY-144710

FLT3/ITD-IN-2	FLT3	Cancer
FLT3/ITD-IN-2 (Compound 17) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 1.0 nM against FLT3 ^D835Y, FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-2 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-175040

PROTAC FLT-3 degrader 5	PROTACs Molecular Glues FLT3 IKZF Family	Cancer
PROTAC FLT-3 degrader 5 is a FLT3 PROTAC degrader (DC₅₀ = 1.2 nM). PROTAC FLT-3 degrader 5 functions as a molecular glue to degrade cereblon substrates GSPT1 and IKZF1/3. PROTAC FLT-3 degrader 5 exhibits antiproliferative activity against drug-resistant acute myeloid leukemia (AML) cells and is potentially useful in AML research. (Pink: FLT3/GSPT1/IKZF1/3 ligand: (HY-169374); Blue: Thalidomide: (HY-14658); Black: linker; Thalidomide + linker: (HY-W1123823)) .

HY-168860

Antituberculosis agent-13	Bacterial	Infection Cancer
Antituberculosis agent-13 (Compound 11) inhibits Mycobacterium tuberculosis, that inhibits Mtb wildtype and mutated strains with IC₅₀ of 4-62.5 nM. Antituberculosis agent-13 exhibits anti-leukemia activity that inhibits MOLM-13 with IC₅₀ of 3.8 μM .

HY-164607

YL-5092	DNA/RNA Synthesis Apoptosis	Cancer
YL-5092 is a selective YT521-B homology (YTH) domain-containing protein 1 (YTHDC1) inhibitor with an IC₅₀ of 7.4 nM and a K_D of 29.6 nM. YL-5092 can suppress cancer cell proliferation and induce cell G0/G1 phase arrest and apoptosis. YL-5092 can be used for the research of cancer, such as acute myeloid leukemia (AML) .

HY-161494

XYD190	PROTACs Epigenetic Reader Domain	Cancer
XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC₅₀ of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161496)) .

HY-158974

YTHDC1-IN-1	DNA/RNA Synthesis Apoptosis PARP	Cancer
YTHDC1-IN-1 is a selective YTHDC1 inhibitor with a K_d of 49 nM and an IC₅₀ of 0.35 μM. YTHDC1-IN-1 can inhibit the proliferation and induce apoptosis of acute myeloid leukemia cell lines. YTHDC1-IN-1 has anti-tumor activity .

HY-170673

E3 Ligase Ligand-linker Conjugate 156	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 156 is a CRBN E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 156 can be used to synthesize PROTAC XPO1 degrader-1 (HY-170669) .

HY-161498

XYD198	PROTACs Epigenetic Reader Domain	Cancer
XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC₅₀ of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161499))

HY-161497

Thalidomide-benzylamine-Py-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-benzylamine-Py-NH2 is a conjugate of E3 ligase ligand and linker, which is consisted of a Thalidomide (HY-14658) and the Linker Boc-NHCH2-Ph-Py-NH2 (HY-161496). Thalidomide-benzylamine-Py-NH2 is utilized for synthesis of PROTAC molecule XYD190 (HY-161494) .

HY-161500

Thalidomide-NHCH2-Ph-pyrimidine-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NHCH2-Ph-pyrimidine-NH2 is a conjugate of E3 ligase ligand and linker, which is consisted of a Thalidomide (HY-14658) and a Linker Boc-NHCH2-Ph-pyrimidine-NH2 (HY-161499). Thalidomide-NHCH2-Ph-pyrimidine-NH2 is utilized for synthesis of PROTAC molecule XYD198 (HY-161498) .

HY-161496

Boc-NHCH2-Ph-Py-NH2	PROTAC Linkers	Cancer
Boc-NHCH2-Ph-Py-NH2 is the linker for PROTAC molecule XYD190 (HY-161494) .

HY-161499

Boc-NHCH2-Ph-pyrimidine-NH2	PROTAC Linkers	Cancer
Boc-NHCH2-Ph-pyrimidine-NH2 is the linker for PROTAC molecule XYD198 (HY-161498) .

HY-143286

PF15	PROTACs FLT3	Cancer
PF15 is a PROTAC connected by ligands for FLT3 kinase and CRBN. PF15 is a high selective FLT3-ITD degrader, with a DC₅₀ of 76.7 nM. PF15 significantly inhibits the proliferation of FLT3-ITD-positive cells, can down-regulate the phosphorylation of FLT3 and STAT5. PF15 also inhibits tumor growth in mouse models and can be used in study of leukemia .

HY-175885

PROTAC FTO degrader 1	PROTACs Fat Mass and Obesity-associated Protein (FTO) Apoptosis Caspase PARP YTHDF	Cancer
PROTAC FTO degrader 1 is a Fat Mass and Obesity-associated Protein (FTO) PROTAC degrader. PROTAC FTO degrader 1 selectively degrades FTO depending on VHL E3 ligase and ubiquitin-proteasome system. PROTAC FTO degrader 1 can increase m₆A modifications on mRNAs associated with ribosome biogenesis and promote their YTHDF2-mediated decay. PROTAC FTO degrader 1 can inhibit cancer cells proliferation and induce apoptosis. PROTAC FTO degrader 1 can be used for the research of cancer, such as acute myeloid leukemia (AML) . (Structure Note: Pink: FTO ligand (HY-175886); Blue: VHL ligand (HY-112078); Black: linker (HY-W002042); VHL ligand-Linker: (HY-139218))

HY-143317

XY153	Epigenetic Reader Domain	Cancer
XY153 (compound 8l) is a BD2-selective BET inhibitor and selectively binds to BRD4 BD2. XY153 binds to BRD4 BD2, BRD3 BD2 and BRD2 BD2 with IC₅₀s of 0.79, 5.31 and 5.09 nM, respectively. XY153 shows potent antiproliferative activity against multiple tumor cell lines. XY153 can be used for the research of acute myeloid leukemia (AML) and cancer .

HY-149031

DHODH-IN-22	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-22 is a potent, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

AML，MOLM-13

Inhibitors & Agonists